Incyte Stock Insiders

INCY -  USA Stock  

USD 64.97  1.58  2.37%

Incyte Corp employes about 1.8 K people. The company is managed by 22 executives with total tenure of roughly 161 years, averaging almost 7.0 years of service per executive having 80.59 employees per reported executive. Break down of Incyte Corp management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Incyte Corp future performance.
Please see Risk vs Return Analysis.

Incyte Insiders 

 
Refresh
  Herve Hoppenot  Chairman
Chairman, CEO and President and Member of Non-Management Stock Option Committee
  Julian Baker  Chairman
Independent Vice Chairman of the Board
  David Gryska  President
CFO, Executive Vice President

Incyte Corp Return on Sales

(0.0928)Share

Incyte Corp Management Team Effectiveness

Incyte Corp has return on total asset (ROA) of 7.54 % which means that it generated profit of $7.54 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 12.79 %, meaning that it created $12.79 on every $100 dollars invested by stockholders. Incyte Corp management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -9 in 2021. Return on Average Assets is likely to drop to -0.1 in 2021. Incyte Corp Total Assets are fairly stable at the moment as compared to the past year. Incyte Corp reported Total Assets of 3.56 Billion in 2020. Assets Non Current is likely to rise to about 1.3 B in 2021, whereas Current Assets are likely to drop slightly above 1.9 B in 2021.

Incyte Corp Quarterly Total Assets

3.9 BillionShare
Issuance Purchase of Equity Shares is likely to rise to about 126.6 M in 2021, whereas Weighted Average Shares is likely to drop slightly above 215.3 M in 2021.

Incyte Corp Workforce Comparison

Incyte Corp is currently regarded as number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 2,867. Incyte Corp totals roughly 1,773 in number of employees claiming about 62% of stocks in Biotechnology industry.

Incyte Corp Profit Margins

The company has Profit Margin (PM) of 12.41 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 15.77 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.16.

Incyte Corp Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Incyte Corp insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Incyte Corp Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Incyte Corp Price Series Summation is a cross summation of Incyte Corp price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Incyte Corp Notable Stakeholders

An Incyte Corp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Incyte Corp often face trade-offs trying to please all of them. Incyte Corp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Incyte Corp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Herve Hoppenot - Chairman, CEO and President and Member of Non-Management Stock Option CommitteeProfile
Julian Baker - Independent Vice Chairman of the BoardProfile
David Gryska - CFO, Executive Vice PresidentProfile
Steven Stein - Senior Vice President and Chief Medical OfficerProfile
Wenqing Yao - Executive Vice President - Discovery Medicinal and Process ChemistryProfile
Eric Siegel - Executive Vice President General CounselProfile
Vijay Iyengar - Executive Vice President Global Strategy and Corporate Development`Profile
Richard Levy - Executive Vice President Chief Drug Development and Medical OfficerProfile
Maria Pasquale - Executive Vice President General CounselProfile
Barry Flannelly - Executive Vice President - Business Development and Strategic PlanningProfile
Christiana Stamoulis - CFO, Executive Vice PresidentProfile
Dashyant Dhanak - Executive Vice President Chief Scientific OfficerProfile
Reid Huber - Chief Scientific Officer and Executive VPProfile
Paula Swain - Executive VP of HRProfile
Paul Friedman - DirectorProfile
Jacqualyn Fouse - DirectorProfile
Paul Clancy - DirectorProfile
Wendy Dixon - Independent DirectorProfile
JeanJacques Bienaime - Independent DirectorProfile
Paul Brooke - Independent DirectorProfile
Paul Trower - Principal Accounting Officer and VP of Fin.Profile
Michael Booth - VP - Investor RelationsProfile

About Incyte Corp Management Performance

The success or failure of an entity such as Incyte Corp often depends on how effective the management is. Incyte Corp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Incyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Incyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Investment(8.34) (9.00) 
Return on Average Assets(0.09) (0.1) 
Return on Average Equity(0.13) (0.13) 
Return on Invested Capital(0.23) (0.24) 
Return on Sales(0.09) (0.09) 
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1773 people.
The data published in Incyte Corp's official financial statements usually reflect Incyte Corp's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Incyte Corp. For example, before you start analyzing numbers published by Incyte accountants, it's critical to develop an understanding of what Incyte Corp's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Incyte Corp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Incyte Corp's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Incyte Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Incyte Corp. Please utilize our Beneish M Score to check the likelihood of Incyte Corp's management to manipulate its earnings.

Incyte Corp Workforce Analysis

Traditionally, organizations such as Incyte Corp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Incyte Corp within its industry.

Incyte Corp Manpower Efficiency

Return on Incyte Corp Manpower

Revenue Per Employee1.2 M
Revenue Per Executive123.6 M
Net Loss Per Employee170.7 K
Net Income Per Executive15.3 M
Working Capital Per Employee380.4 K
Working Capital Per Executive30.7 M
Today, most investors in Incyte Corp Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Incyte Corp's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Incyte Corp per employee as a starting point in their analysis.

Per Employee

Incyte Corp Per Employee Growth Over Time

Net Income Per Employee

(170,699)Share
Incyte Corp Net Income Per Employee is fairly stable at the moment as compared to the past year. Incyte Corp reported Net Income Per Employee of (166,322) in 2020

Revenue Per Employee

1.21 MillionShare
Incyte Corp Revenue Per Employee is fairly stable at the moment as compared to the past year. Incyte Corp reported Revenue Per Employee of 1.5 Million in 2020
Please see Risk vs Return Analysis. Note that the Incyte Corp information on this page should be used as a complementary analysis to other Incyte Corp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Incyte Stock analysis

When running Incyte Corp price analysis, check to measure Incyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte Corp is operating at the current time. Most of Incyte Corp's value examination focuses on studying past and present price action to predict the probability of Incyte Corp's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Incyte Corp's price. Additionally, you may evaluate how the addition of Incyte Corp to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Incyte Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte Corp. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Incyte Corp is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte Corp's value that differs from its market value or its book value, called intrinsic value, which is Incyte Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte Corp's market value can be influenced by many factors that don't directly affect Incyte Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine Incyte Corp value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.